BACKGROUND: To compare the usefulness of four prognostic scores in patients with peripheral T-cell lymphoma (PTCL) from a single institution. PATIENTS AND METHODS: One hundred twenty-one patients (77 male/36 female, median age 53 years) with PTCL [anaplastic large-cell lymphoma (ALCL) 21, PTCL not otherwise specified 56 and other 44)]. Complete response (CR) rate and 5-year overall survival (OS) were 41% and 31%, respectively. International Prognostic Index (IPI), Prognostic Index for T-cell lymphoma (PIT), International peripheral T-cell lymphoma Project score (IPTCLP) and modified Prognostic Index for T-cell lymphoma (mPIT) were calculated as in the original references. mPIT was only assembled to 41 patients in whom Ki-67 immunostaining was available. ALCL patients were analyzed separately. RESULTS: Concordance among IPI, PIT and IPTCLP was 52% for low-risk group, 27% for low/intermediate-risk group, 20% for high/intermediate-risk group and 14% for high-risk group. IPI, PIT and IPTCLP predicted CR, with IPI being the best score in logistic regression. Neither Ki-67 immunostaining nor mPIT predicted CR. Five-year OS (low-risk versus intermediate- or high-risk categories) according to IPI, PIT, IPTCLP and mPIT were 52% versus 45%, 75% versus 49%, 58% versus 20% and 39% versus 0%, respectively. IPTCLP was the best score for OS in multivariate analysis. CONCLUSION: All the scores demonstrated their usefulness to assess the outcome of patients with PTCL, with IPTCLP being the most significant to predict OS.
BACKGROUND: To compare the usefulness of four prognostic scores in patients with peripheral T-cell lymphoma (PTCL) from a single institution. PATIENTS AND METHODS: One hundred twenty-one patients (77 male/36 female, median age 53 years) with PTCL [anaplastic large-cell lymphoma (ALCL) 21, PTCL not otherwise specified 56 and other 44)]. Complete response (CR) rate and 5-year overall survival (OS) were 41% and 31%, respectively. International Prognostic Index (IPI), Prognostic Index for T-cell lymphoma (PIT), International peripheral T-cell lymphoma Project score (IPTCLP) and modified Prognostic Index for T-cell lymphoma (mPIT) were calculated as in the original references. mPIT was only assembled to 41 patients in whom Ki-67 immunostaining was available. ALCL patients were analyzed separately. RESULTS: Concordance among IPI, PIT and IPTCLP was 52% for low-risk group, 27% for low/intermediate-risk group, 20% for high/intermediate-risk group and 14% for high-risk group. IPI, PIT and IPTCLP predicted CR, with IPI being the best score in logistic regression. Neither Ki-67 immunostaining nor mPIT predicted CR. Five-year OS (low-risk versus intermediate- or high-risk categories) according to IPI, PIT, IPTCLP and mPIT were 52% versus 45%, 75% versus 49%, 58% versus 20% and 39% versus 0%, respectively. IPTCLP was the best score for OS in multivariate analysis. CONCLUSION: All the scores demonstrated their usefulness to assess the outcome of patients with PTCL, with IPTCLP being the most significant to predict OS.
Authors: Malte Roerden; Juliane S Walz; Martin R Müller; Martin Sökler; Birgit Federmann; Lothar Kanz; Wolfgang Bethge; Wichard Vogel Journal: J Cancer Res Clin Oncol Date: 2019-08-13 Impact factor: 4.553
Authors: Gerald G Wulf; Bettina Altmann; Marita Ziepert; Francesco D'Amore; Gerhard Held; Richard Greil; Olivier Tournilhac; Thomas Relander; Andreas Viardot; Martin Wilhelm; Christian Wilhelm; Antonio Pezzutto; Josee M Zijlstra; Eric Van Den Neste; Pieternella J Lugtenburg; Jeanette K Doorduijn; Michel van Gelder; Gustaaf W van Imhoff; Florian Zettl; Friederike Braulke; Maike Nickelsen; Bertram Glass; Andreas Rosenwald; Philippe Gaulard; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper Journal: Leukemia Date: 2020-05-07 Impact factor: 11.528
Authors: Amer Beitinjaneh; Rima M Saliba; L Jeffrey Medeiros; Francesco Turturro; Gabriela Rondon; Martin Korbling; Luis Fayad; Michelle A Fanale; Amin M Alousi; Paolo Anderlini; Oran Betul; Uday R Popat; Barbara Pro; Issa F Khouri Journal: Biol Blood Marrow Transplant Date: 2015-01-31 Impact factor: 5.742
Authors: S M Rodríguez-Pinilla; M E C Sánchez; J Rodríguez; J F García; B Sánchez-Espiridión; L F Lamana; G Sosa; J C Rivero; J Menárguez; I B Gómez; F I Camacho; P R Guillen; C P S Orduña; G Rodríguez; C Barrionuevo; R Franco; M Mollejo; J F Marco; R D de Otazu; M A Piris Journal: Blood Cancer J Date: 2013-04-19 Impact factor: 11.037